Interventions in the Treatment and Prevention of Adult Cancer Cachexia
Studies are shedding light on this long-misunderstood and devastating condition that may soon have approved treatments to help prolong cancer patients’ lives.
Human Alpha-1 Antitrypsin Improves Early Posttransplant Lung Function in Pig Lung Transplant Model
Investigators at Toronto General Research Institute used a pig lung transplant model to determine whether human A1AT could attenuate reperfusion injury after prolonged hypothermic preservation.
Going Up: What’s Behind the Growth in IVIG Demand
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Toward the Ultimate Cure: Gene Therapy for Severe Combined Immunodeficiency
Gene therapy is the one remaining therapeutic option for treating severe combined immunodeficiency by correcting it at its most fundamental genetic level.
Stem Cell Therapies: The Era of Regenerative Medicine?
Advancements in stem cell therapy may soon eliminate surgeries and cure disease, but first, the debate between two different schools of thought concerning how best to proceed needs to be resolved.
Recombinant Human Soluble Thrombomodulin May Improve Outcomes in Transplant-Associated Thrombotic Microangiopathy
Intravenous administration of recombinant soluble thrombomodulin (rTM) may improve recovery and survival compared to other treatments in patients with transplant-associated thrombotic microangiopathy (TA-TMA) after hematopoietic stem cell transplantation (HSCT), according to a retrospective analysis of 254 consecutive patients at a single Japanese institution.
Transforming Hemophilia Care: A New Generation of Extended Half-Life Factor Concentrates
New extended half-life products represent a powerful new tool for improving the care and quality of life for persons with hemophilia.
Using Genomic Data to Personalize Cancer Treatment
Researchers are using genomics research to better understand how genetic variation contributes to human health and disease.
The New Therapeutic Renaissance for Patients with Rare Bleeding Disorders
As it has since the first commercially produced factor VIII concentrate transformed the lives of U.S. hemophilia A patients, innovation is still the life-blood of this industry.
